During the past decade, University at Buffalo Clinical and Translational Research Center conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 5 clinical trials were completed, i.e. on average, 45.5% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 4 clinical trials were completed. i.e. 400% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University at Buffalo Clinical and Translational Research Center" #1 sponsor was "Gilead Sciences" with 2 trials, followed by "Intercept Pharmaceuticals" with 2 trials sponsored, "Pfizer" with 2 trials sponsored, "Presidio Pharmaceuticals, Inc." with 2 trials sponsored and "Eli Lilly and Company" with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University at Buffalo Clinical and Translational Research Center" #1 collaborator was "EMD Serono" with 1 trials as a collaborator, "GlaxoSmithKline" with 1 trials as a collaborator, "Lantheus Medical Imaging" with 1 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator and "State University of New York at Buffalo" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "University at Buffalo Clinical and Translational Research Center" are "Nonalcoholic Steatohepatitis" (4 trials), "Pharmacokinetic Assessments in Healthy Volunteers" (2 trials), "Allergy" (1 trials), "Allergy Skin" (1 trials) and "Compensated Cirrhosis" (1 trials). Many other conditions were trialed in "University at Buffalo Clinical and Translational Research Center" in a lesser frequency.

Most popular intervention types in "University at Buffalo Clinical and Translational Research Center" are "Drug" (12 trials), "Biological" (2 trials), "Device" (1 trials), "Diagnostic Test" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "PPI-668 capsule" (2 trials), "PPI-668 tablet" (2 trials), "Placebo to match SEL 18 mg" (2 trials) and "Placebo to match SEL 6 mg" (2 trials). Other intervention names were less common.

The vast majority of trials in "University at Buffalo Clinical and Translational Research Center" are 16 trials for "All" genders.

Currently, there are NaN active trials in "University at Buffalo Clinical and Translational Research Center". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in University at Buffalo Clinical and Translational Research Center, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in University at Buffalo Clinical and Translational Research Center, 6 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".